Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: John F Beule who wrote (5726)	12/3/1998 10:16:00 AM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Agouron sets trial for cold virus inhibitor Reuters, Thursday, December 03, 1998 at 09:46 NEW YORK, Dec 3 (Reuters) - Agouron Pharmaceuticals Inc. (NASDAQ:AGPH) said Thursday it would begin a Phase I trial in England this month to fight the common cold virus using a protease inhibitor that it has developed. The company spokeswoman, Donna Nichols, told Reuters the trial will probably last six months to a year employing the company's compound AG7080, which she said inhibits the so-called 3C protease that the Rhinovirus needs to replicate. The Rhinovirus causes the common cold. She said details of the trial have not been divulged but Agouron owns all rights to the compound, which it designed and developed. She said the compound is an intranasal formulation that has finished toxicology studies. "Clinical trials will begin in England this month," she said at the BancBoston Robertson Stephens medical conference in New York. Agouron, based in La Jolla, California, is best known for Viracept, its market-leading protease inhibitor against the HIV virus that causes AIDS. Nichols said the Rhinovirus protease is essential for making mature viruses. "Protease cleaves a polyprotein so that the mature rhinovirus can be expelled from one cell and invade other healthy cells," Nichols said. Copyright 1998, Reuters News Service